Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of PCOS among women of reproductive age
3.2.1.2 Rising awareness and diagnosis
3.2.1.3 Support from government and non-governmental organizations
3.2.1.4 Rising incidence of obesity and sedentary lifestyle
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects of medication
3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.4.3 Asia Pacific
3.5 Pipeline analysis
3.6 Future market trends
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Medications
5.2.1 By drug class
5.2.1.1 Oral contraceptives
5.2.1.2 Antiandrogen
5.2.1.3 Insulin-sensitizing agents
5.2.1.4 Antidepressants
5.2.1.5 Anti-obesity
5.2.1.6 Selective Estrogen Receptor Modulators (SERMs)
5.2.1.7 Other drug classes
5.2.2 By distribution channel
5.2.2.1 Hospital pharmacies
5.2.2.2 Retail pharmacies
5.2.2.3 Online pharmacies
5.3 Surgery
5.3.1 Ovarian wedge resection
5.3.2 Laparoscopic ovarian drilling
5.3.3 Other surgeries
Chapter 6 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 Germany
6.3.2 UK
6.3.3 France
6.3.4 Spain
6.3.5 Italy
6.3.6 Netherlands
6.3.7 Rest of Europe
6.4 Asia Pacific
6.4.1 China
6.4.2 Japan
6.4.3 India
6.4.4 Australia
6.4.5 South Korea
6.4.6 Rest of Asia Pacific
6.5 Latin America
6.5.1 Brazil
6.5.2 Mexico
6.5.3 Rest of Latin America
6.6 Middle East and Africa
6.6.1 South Africa
6.6.2 Saudi Arabia
6.6.3 UAE
6.6.4 Rest of Middle East and Africa
Chapter 7 Company Profiles
7.1 Abbott Laboratories
7.2 AbbVie Plc
7.3 Addex Therapeutics Ltd.
7.4 AstraZeneca PLC
7.5 Bayer AG
7.6 Bristol-Myer Squibb Company
7.7 Ferring BV
7.8 Johnson and Johnson
7.9 Merck KGaA
7.10 Mylan N.V
7.11 Novartis AG
7.12 Pfizer Inc.
7.13 Sanofi SA
7.14 Takeda Pharmaceutical Company Limited
7.15 Teva Pharmaceutical Industries Limited
